Skip to main content
. Author manuscript; available in PMC: 2011 Jun 20.
Published in final edited form as: Virology. 2010 Apr 8;402(1):102–111. doi: 10.1016/j.virol.2010.02.031

Figure 2.

Figure 2

Abrogation of the immunodominant CTL response to TMEV in SJL mice does not influence the initiation or progression of clinical disease or the CNS viral titer. SJL mice were injected i.v. with 100 μg VP3159–166 or sham peptide in PBS 7 days prior to TMEV infection. (A) Mice were monitored for disease progression as outlined in the materials and methods for at least 75 days. Data are representative of 4 separate experiments containing at least 5 mice per group per experiment. At early (days 4 and 9 p.i.) and late (day 42 p.i.) time-points, brain (B) and spinal cord tissues (C) were harvested from 3 mice per group and assessed for the presence of replicating virus by plaque assay. Data are representative of 3 separate experiments at similar time-points. No significant difference between sham peptide and VP3159–166 recipient mice was observed at any time point in terms of disease score or CNS viral titer.